R&D News | pharmaphorum

News

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

News

Kardigan makes its debut with a teal of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.

News

AI startup Bioptimus takes its funding above $76m as it prepares for the launch of a universal foundation model for pathology later this year.

News

Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.

News

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.